Tandem Diabetes Care Inc (NASDAQ: TNDM) announced on Wednesday that it has launched the t:slim X2 insulin pump integrated with Abbott's FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) sensor in the US, marking the start of a global rollout of the combined technologies.

The integration pairs Tandem's Control-IQ+ automated insulin delivery technology with Abbott's 15-day wear FreeStyle Libre 3 Plus sensor, which transmits glucose readings every minute directly to the pump. The system automatically adjusts insulin every five minutes and includes AutoBolus, a feature that calculates and delivers corrective doses to reduce the impact of missed meal boluses.

Updated software enabling the integration is preloaded on all new t:slim X2 pump shipments in the US and available free of charge to eligible existing users via remote update. Tandem plans to launch early-access programs internationally later this year, with broader commercial rollout expected in 2026.

Based in San Diego, Tandem Diabetes Care develops automated insulin delivery systems, including the t:slim X2 and Tandem Mobi pumps, designed to reduce the daily burden of diabetes management.